LRCX
37
-9
YUM
43
-6
DGX
48
11
DLTR
38
-4
CVX
43
-3
HCP
56
-8
CNX
73
-3
PEP
39
-9
DD
53
-6
PSA
56
3
NWSA
62
-7
RSG
65
-3
CMA
61
-3
NEM
40
3
CSCO
58
-2
ZBH
65
3
EFX
30
-8
AIZ
82
2
GD
41
-4
CCI
30
-11
LRCX
37
-9
YUM
43
-6
DGX
48
11
DLTR
38
-4
CVX
43
-3
HCP
56
-8
CNX
73
-3
PEP
39
-9
DD
53
-6
PSA
56
3
NWSA
62
-7
RSG
65
-3
CMA
61
-3
NEM
40
3
CSCO
58
-2
ZBH
65
3
EFX
30
-8
AIZ
82
2
GD
41
-4
CCI
30
-11
Financhill
Back

Lixte Biotechnology Holdings 10K Form

Sell
18

LIXT
Lixte Biotechnology Holdings

Last Price:
1.69
Seasonality Move:
2.1%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive LIXT News And Ratings

See the #1 stock for the next 7 days that we like better than LIXT

LIXT Financial Statistics

Sales & Book Value

Annual Sales: $200K
Cash Flow: $-819K
Price / Cash Flow: 0
Annual Sales: $-0.56
Price / Book: 0

Profitability

EPS (TTM): -1.78000
Net Income (TTM): $-4.03M
Gross Margin: $0
Return on Equity: 0%
Return on Assets: 0%

Lixte Biotechnology Holdings Earnings Forecast

Key Lixte Biotechnology Holdings Financial Ratios

  • The Selling, General & Administrative Expenses for LIXT have been equal to 377.22% of Gross Profit Margin.
  • The Interest Expense is -0.32% of Operating Income.
  • Per Share Earnings over the last 19 years have been positive in 8 years.

Lixte Biotechnology Holdings Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: LIXT
Website: lixte.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

LIXT Technical Analysis vs Fundamental Analysis

Sell
18
Lixte Biotechnology Holdings (LIXT) is a Sell

Is Lixte Biotechnology Holdings a Buy or a Sell?